Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights ...
Nov 7, 2024 · srpt Total Revenue: $467.2 million for Q3 2024, up from $331 million in Q3 2023. Net Product Revenue: $181 million from Elevidys, compared to $69 million in Q3 2023.
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker …
1 day ago · To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September ...
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based …
Nov 7, 2024 · SRPT product revenues rose 39% year over year to about $430 million, driven by increased demand for its marketed products. The metric beat the Zacks Consensus Estimate and our model estimate of ...
Sarepta Therapeutics Announces FDA Approval of ...
Jun 22, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jun. 22, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus …
Sarepta Therapeutics (SRPT) Stock Surges on Gene Therapy …
Jun 20, 2024 · A top US Food and Drug Administration official overrode reviewers to give broad approval to Sarepta Therapeutics Inc.’s gene therapy for a rare muscle disease in children, despite a lack of data ...
Sarepta Therapeutics Announces Topline Results from EMBARK, a …
Oct 30, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Oct. 30, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced topline results from EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of …
Sarepta upgraded at Cantor on pipeline, growth potential
Nov 7, 2024 · Cantor Fitzgerald has upgraded Sarepta Therapeutics (NASDAQ: SRPT) to overweight from neutral signaling that the company's growth could be higher than the Street is estimating and citing the ...
Sarepta Therapeutics’ stock soars 38% after FDA expands use of its ...
Jun 21, 2024 · Sarepta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder...
Sarepta Therapeutics Inc. Stock Quote (U.S. - SRPT - MarketWatch
2 days ago · SRPT | Complete Sarepta Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
Nov 7, 2024 · SRPT earnings call for the period ending September 30, 2024. Image source: The Motley Fool. Sarepta Therapeutics (SRPT 2.37%) Q3 2024 Earnings Call. Nov 06, 2024, 4:30 p.m. ET.